Brief: Vir Biotechnology Presents New Data Evaluating The Potential For Vir-2218 And Vir-3434 As Therapies For Chronic Hepatitis B And Hepatitis D
24/06/2023 10:33
Vir Biotechnology Inc VIR.O :
* VIR BIOTECHNOLOGY PRESENTS NEW DATA EVALUATING THE
POTENTIAL FOR
VIR-2218 AND VIR-3434 AS THERAPIES FOR CHRONIC HEPATITIS B AND
HEPATITIS D
* VIR BIOTECHNOLOGY - PRECLINICAL DATA SUGGEST POTENTIAL
OF
VIR-2218, VIR-3434 AS TREATMENT FOR CHRONIC SUPPRESSION OF
HEPATITIS D VIRUS INFECTION
Source text for Eikon: ID:nGNX3kHv0R
Further company coverage: VIR.O
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO